Novavax (NVAX) Convertible Debt (2016 - 2025)

Novavax's Convertible Debt history runs 10 years deep, the most recent figure standing at $244.2 million for Q4 2025.

• On a quarterly basis, Convertible Debt rose 43.92% year-over-year to $244.2 million in Q4 2025; TTM through Dec 2025 was $244.2 million, a 43.92% increase from a year earlier, with the FY2025 full-year figure at $244.2 million, up 43.92% from the prior year.
• Convertible Debt steadied at $244.2 million in Q4 2025 per NVAX's latest filing, from $243.8 million in the prior quarter.
• Across five years, Convertible Debt topped out at $324.5 million in Q3 2022 and bottomed at $166.5 million in Q4 2022.
• The 5-year median for Convertible Debt is $170.1 million (2025), against an average of $225.3 million.
• Across the five-year window, Convertible Debt slumped 48.54% in 2022 and surged 44.06% in 2025, its largest moves.
• Year by year, Convertible Debt stood at $323.5 million in 2021, then sank by 48.54% to $166.5 million in 2022, then gained by 0.93% to $168.0 million in 2023, then increased by 0.99% to $169.7 million in 2024, then surged by 43.92% to $244.2 million in 2025.
• Per Business Quant, the three latest NVAX Convertible Debt figures stand at $244.2 million (Q4 2025), $243.8 million (Q3 2025), and $170.6 million (Q2 2025).